Differential Suppressive Effects of Rho Kinase Inhibitor Fasudil on Serotonin- and Noradrenaline-Induced Contractions of Human Internal Thoracic Arteries and Saphenous Veins.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY Biological & pharmaceutical bulletin Pub Date : 2024-01-01 DOI:10.1248/bpb.b24-00502

Takayuki Matsumoto, Takayuki Nagano, Atsuko Yokota, Eisaku Nakamura, Masachika Kuwabara, Ryuichi Yamamoto, Naoko Tanaka-Totoribe

{"title":"Differential Suppressive Effects of Rho Kinase Inhibitor Fasudil on Serotonin- and Noradrenaline-Induced Contractions of Human Internal Thoracic Arteries and Saphenous Veins.","authors":"Takayuki Matsumoto, Takayuki Nagano, Atsuko Yokota, Eisaku Nakamura, Masachika Kuwabara, Ryuichi Yamamoto, Naoko Tanaka-Totoribe","doi":"10.1248/bpb.b24-00502","DOIUrl":null,"url":null,"abstract":"<p><p>Rho kinase inhibitor fasudil exerts therapeutic effects against vasospasms. In this study, we aimed to compare its suppressive effects on serotonin (5-HT)- and noradrenaline (NAd)-induced contractions of human endothelium-denuded internal thoracic arteries (ITAs) and saphenous veins (SVs). NAd and 5-HT induced concentration-dependent contractions in both ITAs and SVs. However, fasudil (3 µmol/L) pretreatment decreased these constrictor-induced contractions in both ITAs and SVs. Fasudil exerted similar inhibitory effects on 5-HT and NAd in ITAs. However, in SVs, fasudil exerted stronger inhibitory effects on NAd-induced contractions than on 5-HT-induced contractions. Therefore, inhibitory effects of fasudil on 5-HT-induced contractions were stronger in ITAs than in SVs. Overall, these results suggest that Rho kinases exert different effects on the two vasoconstrictors in SVs, but not in ITAs, thus explaining their different graft patencies.</p>","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 10","pages":"1657-1661"},"PeriodicalIF":1.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological & pharmaceutical bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1248/bpb.b24-00502","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Rho kinase inhibitor fasudil exerts therapeutic effects against vasospasms. In this study, we aimed to compare its suppressive effects on serotonin (5-HT)- and noradrenaline (NAd)-induced contractions of human endothelium-denuded internal thoracic arteries (ITAs) and saphenous veins (SVs). NAd and 5-HT induced concentration-dependent contractions in both ITAs and SVs. However, fasudil (3 µmol/L) pretreatment decreased these constrictor-induced contractions in both ITAs and SVs. Fasudil exerted similar inhibitory effects on 5-HT and NAd in ITAs. However, in SVs, fasudil exerted stronger inhibitory effects on NAd-induced contractions than on 5-HT-induced contractions. Therefore, inhibitory effects of fasudil on 5-HT-induced contractions were stronger in ITAs than in SVs. Overall, these results suggest that Rho kinases exert different effects on the two vasoconstrictors in SVs, but not in ITAs, thus explaining their different graft patencies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Rho 激酶抑制剂法舒地尔对羟色胺和去甲肾上腺素诱导的人胸内动脉和隐静脉收缩的不同抑制作用

Rho 激酶抑制剂法舒地尔对血管痉挛有治疗作用。在这项研究中，我们的目的是比较它对5-羟色胺（5-HT）和去甲肾上腺素（NAd）诱导的人胸内动脉（ITA）和隐静脉（SV）收缩的抑制作用。NAd和5-HT可诱导ITA和SV发生浓度依赖性收缩。然而，法舒地尔（3 µmol/L）预处理可减少这些收缩剂诱导的ITA和SV收缩。法舒地尔对 ITAs 中的 5-HT 和 NAd 具有类似的抑制作用。然而，在 SV 中，法舒地尔对 NAd 诱导的收缩的抑制作用强于对 5-HT 诱导的收缩的抑制作用。因此，法舒地尔对 5-HT 诱导的收缩的抑制作用在 ITAs 中比在 SV 中更强。总之，这些结果表明，Rho 激酶在 SV 中对两种血管收缩剂产生不同的作用，而在 ITAs 中则没有，这也解释了它们不同的移植通畅性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biological & pharmaceutical bulletin 医学-药学

CiteScore

3.50

自引率

5.00%

发文量

247

审稿时长

2 months

期刊介绍： Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.